Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection

Part of paid clinical trials in New York, New York.

Sponsor
Newish Biotech (Wuxi) Co., Ltd.
Study ID
NCT07536282
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Persistent HPV16 Infection

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • NWRD09 — BIOLOGICAL
    Participants will receive 4 injections of NWRD09 via IM to the lateral deltoid region of the upper arm, at D1 (W0D1), D15 (W2D1), D29 (W4D1) and D85 (W12D1)
  • Placebo — BIOLOGICAL
    Participants will receive 4 injections of Placebo via IM to the lateral deltoid region of the upper arm, at D1 (W0D1), D15 (W2D1), D29 (W4D1) and D85 (W12D1)

Study Details

This is a two-part, phase I/IIa study, intended to evaluate the safety, tolerability, immunogenicity, and efficacy of NWRD09 in female participants with persistent HPV16 infection, and to determine the MTD, and/or RP2D of NWRD09.

Key Dates

Start date
Oct 31, 2026
Status verified
Apr 2026
Primary completion
Sep 30, 2027
Completion
Nov 30, 2027

Study Design

Enrollment
78 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: NWRD09
    Predefined dose groups of NWRD09
  • Placebo Comparator: Placebo

Primary Outcome Measure

Incidence and severity of local and systemic adverse events (AEs). [ Time Frame: Up to Week 28 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Columbia University Medical CenterNew YorkNew York10032
June Y. Hou, MD
212-305-3410
June Y. Hou, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in New York, NY